GSK further narrows consumer health focus with sale to Crown Labs of North American distribution rights for PanOxyl acne wash, Sarna anti-itch lotion, Zeasorb anti-fungal product, Desenex athlete’s foot treatment and Mineral Ice pain-relieving gel. Deals also helps UK pharma pay for its $5.1bn acquisition of oncology drug firm Tesaro.
GlaxoSmithKline PLC carved off more of its non-core OTC brands with the sale of North American rights to five derma lines to Crown Laboratories Inc., which is carving out market share across skin care categories.
In addition to further narrowing it consumer health focus, GSK's sale of Canada, Mexico and US distribution rights for PanOxyl daily acne wash and four other brands generates cash to help pay for its recently announced $5.1bn acquisition of oncology drug firm Tesaro Inc
Deal totaling as much as $880m extends C&D into additional product category with a brand it says is the fastest growing in the US hand sanitizer category and No. 2 brand in the category overall.
UK-based Venture Life is divesting its CDMO business and some non-core products to focus its attention on growing its consumer health operation.
Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.
Wellnex bringing brands such as Pain Away, Wakey Wakey and Nighty Night to UK market shortly after gaining admission to the the AIM market of the London Stock Exchange.
UK-based Venture Life is divesting its CDMO business and some non-core products to focus its attention on growing its consumer health operation.
“The situation has evolved considerably” since Kenvue gave its initial full-year outlook in February, “and remains quite fluid,” says president and CEO Thibaut Mongon as firm reports Q1 net sales decreasing 3.9% to $3.7bn
Looming imposition of tariffs by Trump on imports from most every country had an influence on consumers during the January-March period, particularly on online shopping. Increasing product prices on the table, “but our efforts are going to start with cost savings,” says CFO Christine Sacco.
